Nanodiagnostics to face SARS-CoV-2 and future pandemics :: from an idea to the market and beyond

Giulio Rosati; Andrea Idili; Claudio Parolo; Celia Fuentes-Chust; Enric Calucho; Liming Hu; Cecilia De Carvalho Castro Silva; Lourdes Rivas; Emily P. Nguyen; José Francisco Bergua Canudo; Ruslan Álvarez Diduk; José Muñoz; Christophe Junot; Oriol Penon; Dominique Monferrer; Emmanuel Delamarche; Arben Merkoçi

doi:10.1021/acsnano.1c06839

Nanodiagnostics to face SARS-CoV-2 and future pandemics : from an idea to the market and beyond

Giulio Rosati, Andrea Idili, Claudio Parolo, Celia Fuentes-Chust, Enric Calucho, Liming Hu, Cecilia De Carvalho Castro Silva, Lourdes Rivas, Emily P. Nguyen, José Francisco Bergua Canudo, Ruslan Álvarez Diduk, José Muñoz, Christophe Junot, Oriol Penon, Dominique Monferrer, Emmanuel Delamarche, Arben Merkoçi

Department of Physics

Research output: Contribution to journal › Article › Research › peer-review

48 Citations (Scopus)

Abstract

The COVID-19 pandemic made clear how our society requires quickly available tools to address emerging healthcare issues. Diagnostic assays and devices are used every day to screen for COVID-19 positive patients, with the aim to decide the appropriate treatment and containment measures. In this context, we would have expected to see the use of the most recent diagnostic technologies worldwide, including the advanced ones such as nano-biosensors capable to provide faster, more sensitive, cheaper, and high-throughput results than the standard polymerase chain reaction and lateral flow assays. Here we discuss why that has not been the case and why all the exciting diagnostic strategies published on a daily basis in peer-reviewed journals are not yet successful in reaching the market and being implemented in the clinical practice.

Original language	English
Pages (from-to)	17137-17149
Number of pages	13
Journal	ACS Nano
Volume	15
Issue number	11
DOIs	https://doi.org/10.1021/acsnano.1c06839
Publication status	Published - 2021

Keywords

COVID-19
SARS-CoV-2
Nanodiagnostics
Biosensors
Bottlenecks
Outbreaks
Testing methods
Phases of test development

Access to Document

10.1021/acsnano.1c06839

https://ddd.uab.cat/record/250494

Cite this

Rosati, G., Idili, A., Parolo, C., Fuentes-Chust, C., Calucho, E., Hu, L., De Carvalho Castro Silva, C., Rivas, L., Nguyen, E. P., Bergua Canudo, J. F., Álvarez Diduk, R., Muñoz, J., Junot, C., Penon, O., Monferrer, D., Delamarche, E., & Merkoçi, A. (2021). Nanodiagnostics to face SARS-CoV-2 and future pandemics : from an idea to the market and beyond. ACS Nano, 15(11), 17137-17149. https://doi.org/10.1021/acsnano.1c06839

@article{13a9b6819c3f434d9033a10e0202d136,

title = "Nanodiagnostics to face SARS-CoV-2 and future pandemics :: from an idea to the market and beyond",

abstract = "The COVID-19 pandemic made clear how our society requires quickly available tools to address emerging healthcare issues. Diagnostic assays and devices are used every day to screen for COVID-19 positive patients, with the aim to decide the appropriate treatment and containment measures. In this context, we would have expected to see the use of the most recent diagnostic technologies worldwide, including the advanced ones such as nano-biosensors capable to provide faster, more sensitive, cheaper, and high-throughput results than the standard polymerase chain reaction and lateral flow assays. Here we discuss why that has not been the case and why all the exciting diagnostic strategies published on a daily basis in peer-reviewed journals are not yet successful in reaching the market and being implemented in the clinical practice.",

keywords = "COVID-19, SARS-CoV-2, Nanodiagnostics, Biosensors, Bottlenecks, Outbreaks, Testing methods, Phases of test development",

author = "Giulio Rosati and Andrea Idili and Claudio Parolo and Celia Fuentes-Chust and Enric Calucho and Liming Hu and \{De Carvalho Castro Silva\}, Cecilia and Lourdes Rivas and Nguyen, \{Emily P.\} and \{Bergua Canudo\}, \{Jos{\'e} Francisco\} and \{{\'A}lvarez Diduk\}, Ruslan and Jos{\'e} Mu{\~n}oz and Christophe Junot and Oriol Penon and Dominique Monferrer and Emmanuel Delamarche and Arben Merko{\c c}i",

year = "2021",

doi = "10.1021/acsnano.1c06839",

language = "English",

volume = "15",

pages = "17137--17149",

journal = "ACS Nano",

issn = "1936-0851",

publisher = "American Chemical Society",

number = "11",

}

Rosati, G, Idili, A, Parolo, C, Fuentes-Chust, C, Calucho, E, Hu, L, De Carvalho Castro Silva, C, Rivas, L, Nguyen, EP, Bergua Canudo, JF, Álvarez Diduk, R, Muñoz, J, Junot, C, Penon, O, Monferrer, D, Delamarche, E & Merkoçi, A 2021, 'Nanodiagnostics to face SARS-CoV-2 and future pandemics : from an idea to the market and beyond', ACS Nano, vol. 15, no. 11, pp. 17137-17149. https://doi.org/10.1021/acsnano.1c06839

TY - JOUR

T1 - Nanodiagnostics to face SARS-CoV-2 and future pandemics :

T2 - from an idea to the market and beyond

AU - Rosati, Giulio

AU - Idili, Andrea

AU - Parolo, Claudio

AU - Fuentes-Chust, Celia

AU - Calucho, Enric

AU - Hu, Liming

AU - De Carvalho Castro Silva, Cecilia

AU - Rivas, Lourdes

AU - Nguyen, Emily P.

AU - Bergua Canudo, José Francisco

AU - Álvarez Diduk, Ruslan

AU - Muñoz, José

AU - Junot, Christophe

AU - Penon, Oriol

AU - Monferrer, Dominique

AU - Delamarche, Emmanuel

AU - Merkoçi, Arben

PY - 2021

Y1 - 2021

N2 - The COVID-19 pandemic made clear how our society requires quickly available tools to address emerging healthcare issues. Diagnostic assays and devices are used every day to screen for COVID-19 positive patients, with the aim to decide the appropriate treatment and containment measures. In this context, we would have expected to see the use of the most recent diagnostic technologies worldwide, including the advanced ones such as nano-biosensors capable to provide faster, more sensitive, cheaper, and high-throughput results than the standard polymerase chain reaction and lateral flow assays. Here we discuss why that has not been the case and why all the exciting diagnostic strategies published on a daily basis in peer-reviewed journals are not yet successful in reaching the market and being implemented in the clinical practice.

AB - The COVID-19 pandemic made clear how our society requires quickly available tools to address emerging healthcare issues. Diagnostic assays and devices are used every day to screen for COVID-19 positive patients, with the aim to decide the appropriate treatment and containment measures. In this context, we would have expected to see the use of the most recent diagnostic technologies worldwide, including the advanced ones such as nano-biosensors capable to provide faster, more sensitive, cheaper, and high-throughput results than the standard polymerase chain reaction and lateral flow assays. Here we discuss why that has not been the case and why all the exciting diagnostic strategies published on a daily basis in peer-reviewed journals are not yet successful in reaching the market and being implemented in the clinical practice.

KW - COVID-19

KW - SARS-CoV-2

KW - Nanodiagnostics

KW - Biosensors

KW - Bottlenecks

KW - Outbreaks

KW - Testing methods

KW - Phases of test development

UR - https://www.scopus.com/pages/publications/85118930117

U2 - 10.1021/acsnano.1c06839

DO - 10.1021/acsnano.1c06839

M3 - Article

C2 - 34705433

SN - 1936-0851

VL - 15

SP - 17137

EP - 17149

JO - ACS Nano

JF - ACS Nano

IS - 11

ER -

Nanodiagnostics to face SARS-CoV-2 and future pandemics : from an idea to the market and beyond

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this